The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1451
Vorapaxar (Zontivity) for Prevention of Thrombotic Cardiovascular Events
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved vorapaxar (Zontivity – Merck), an oral protease-activated receptor-1 (PAR-1) antagonist, for use with aspirin and/or clopidogrel to reduce the risk of thrombotic cardiovascular events in patients with peripheral arterial disease or a history of myocardial infarction (MI). It is the first PAR-1 antagonist to be approved by the FDA.

STANDARD ANTIPLATELET THERAPY — Aspirin plus clopidogrel, prasugrel, or ticagrelor is the standard of care for prevention of thrombotic cardiovascular events in patients with a history of MI. Prasugrel and ticagrelor are more effective than clopidogrel, but they have been associated with a higher risk of bleeding. In patients with peripheral arterial disease, the standard of care is aspirin alone; if a patient is intolerant to aspirin, clopidogrel can be used.1

ACTIVITY — Thrombin potently ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Vorapaxar (Zontivity) for Prevention of Thrombotic Cardiovascular Events
Article code: 1451a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian